



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 07 Oct 2019 (#33)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • **Stellenbosch Campus** lizelk@sun.ac.za

Important Notices & News

- **FINDINGS OF RESEARCH MISCONDUCT NOT-OD-19-140:** The Office for Research Integrity (ORI) found that Respondent engaged in research misconduct by intentionally, knowingly, and/or recklessly falsifying and/or fabricating data in the unpublished research record by the alteration, reuse, and/or relabeling of quantitative real-time polymerase chain reaction (qRT-PCR) data and colony forming cell (CFC) and focus formation (FF) assay images to represent experiments that measured microRNA expression levels and the effect of long intergenic non-protein coding (LINC) RNAs in human cancer cell lines that were not conducted.
- **NOTICE OF SPECIAL INTEREST NOT-DK-19-019: Nutrigenetics and Nutrigenomics Approaches for Nutrition Research:** The purpose of this Notice of Special Interest is to foster collaborative research between nutrition researchers and experts in omics technologies and encourages applications that employ nutrigenetics and/or nutrigenomics approaches to basic, translational and clinical nutrition research. Collaboration between investigators with demonstrated expertise in nutrition research and omics techniques is highly encouraged.
- **Review of the Accuracy of Grants Information for Fiscal Year 2019 NOT-OD-19-148** As the fiscal year comes to an end on September 30, 2019, NIH encourages Recipient Organizations to verify the accuracy of their grant assignments to Departments or Components within Organizations of Higher Education in eRA Commons through the Grant Re-assign function. Any corrections to the data must be made by 8:00 PM EDT on Friday, October 11, 2019 to be reflected in NIH annual reports.
- **NOT-AA-19-026: Notice of Intent to Publish a Funding Opportunity Announcement for Impact of Alcohol on the Onset and Progression of Alzheimer's Disease and Its Related Dementias (R01 - Clinical Trial Optional)** National Institute on Alcohol Abuse and Alcoholism (NIAAA) in partnership with the National Institute on Aging (NIA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to investigate mechanisms underlying the influence of alcohol on the onset and progression of Alzheimer's disease and its related dementias. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. The FOA is expected to be published in Fall 2019 with an expected application due date in Spring 2020.

1. Tobacco Regulatory Science (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-OD-19-028](#)

Type: R01

Application Due Date: February 13, 2020, July 17, 2020, February 13, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Budget: NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund up to 8 R01s, corresponding to a total of up to \$4 million, for fiscal year 2020. Future year amounts will depend on availability of funds. Application budgets are limited to \$300,000 in direct cost per year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

2. Perception and Cognition Research to Inform Cancer Image Interpretation (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-387](#)
[PAR-19-389](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 -

3. Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-associated Variants (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-19-012](#)

Type: UM1

Application Due Date: December 3, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for large-scale complex multi-disciplinary Functional Genomics Projects (FGPs) to determine the contributions and mechanisms underlying the contribution of risk-associated variants and their downstream effector transcripts for type 2 diabetes (T2D). The intent is to generate knowledge and tools to enable the identification of putative biomarkers and therapeutic targets by future efforts. Genome-wide association studies (GWAS) and other genomic studies of T2D and its complications have found many variants that are statistically associated with disease risk, disease protection, progression to complications, or other traits. However, such studies do not show which variants in genomic elements cause these effects or how they result in differences in function. Applications submitted to this RFA will systematically identify causal variants and effector transcripts associated with all known T2D risk variants, verify the role of downstream effector transcripts, build network models that explain their role(s) in T2D and its complications, and identify key readouts and modulation points in these networks. Data, tools, and reagents generated by these projects will be released rapidly to facilitate more in-depth study by the broad scientific community. Awardees to this announcement will form a Consortium with the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal awardee (AMP T2D KP; RFA-DK-19-505) to accomplish collective goals.

Budget: The NIDDK intends to commit \$3 million in FY 2020 to fund 2 awards. Application budgets are limited to \$1.5 million per year in direct costs. The maximum project period is 5 years.

4. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-390](#)

Type: X01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Budget: Not applicable; there are no funds associated with a resource access award. The maximum project period is 1 year

5. Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-026](#)
[PAR-20-027](#)

Type: U01
Collaborative U01

Application Due Date: February 14, 2020, September 15, 2020, September 15, 2021, September 15, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The following Funding Opportunity Announcement (FOA) seeks applications proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non-European ancestry to advance the important goal of global mental health discovery and equity. This FOA is one of several FOAs supporting a program called, "Ending Disparities in Mental Health" ([EDify-MH](#)).

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period is limited to 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](#)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: [Lizel](#)
e: lizelk@sun.ac.za | t: +27 21 808 2105